Drugs / mBTCvax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06564623 | May 2025 → Mar 2029 expected | biliary tract cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mBTCvax | “personalized mutant peptide vaccine with poly-ICLC adjuvant (mBTCvax)” NCT06564623 ↗ |
| Modality | Vaccine | “personalized mutant peptide vaccine” NCT06564623 ↗ |